Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  IDrugs : the investigational drugs journal

• Publication date

  2007-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 17665331
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dual targeting of epigenetic therapy in cancer.

  2007cited by this paper
• Histone deacetylase inhibitors: signalling towards p21cip1/waf1.

  2007cited by this paper
• Cardiotoxicity of Histone Deacetylase Inhibitor Depsipeptide in Patients with Metastatic Neuroendocrine Tumors

  2006cited by this paper
• Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.

  2006cited by this paper
• Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome

  2006cited by this paper
• Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.

  2006cited by this paper
• Epigenetic therapy of cancer: past, present and future

  2006cited by this paper
• Cardiac Studies in Patients Treated with Depsipeptide, FK228, in a Phase II Trial for T-Cell Lymphoma

  2006cited by this paper
• Anticancer activities of histone deacetylase inhibitors

  2006cited by this paper
• Chromatin modifier enzymes, the histone code and cancer.

  2005cited by this paper

• Epigenetic alterations in prostate cancer: the role of chromatin remodeling.

  2025cites this paper
• Pracinostat combined with azacitidine in newly diagnosed adult acute myeloid leukemia (AML) patients unfit for standard induction chemotherapy: PRIMULA phase III study.

  2024cites this paper
• Effect of 5-azacytidine (5-aza) on UCP2 expression in human liver and colon cancer cells

  2021cites this paper
• Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment.

  2020cites this paper
• Berberine Induces p53-Dependent Apoptosis through Inhibition of DNA Methyltransferase3b in Hep3B Cells

  2020cites this paper
• A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy

  2020cites this paper
• Treatment with 5-azacytidine Increases UCP2 levels in Hep3B and HT-29 Cells but Not in HepG2 Cells

  2020cites this paper
• lnhibitori histonskih deacetilaza kao protutumorski lijekovi

  2020cites this paper
• Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study.

  2019cites this paper
• Role of Zinc in Immune System and Anti-Cancer Defense Mechanisms

  2019cites this paper
• Antimetastatic effect of epigenetic drugs, hydralazine and valproic acid, in Ras-transformed NIH 3T3 cells

  2018cites this paper
• Phase 2, randomized, double‐blind study of pracinostat in combination with azacitidine in patients with untreated, higher‐risk myelodysplastic syndromes

  2017cites this paper
• Phase II Randomized Double-Blinded Study of Pracinostat in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes

  2017cites this paper
• EPIGENOME AS A THERAPEUTIC TARGET FOR LYMPHOMA

  2017cites this paper
• Correlation between mutation clearance and clinical response in elderly patients with acute myeloid leukemia (AML) treated with azacitidine and pracinostat.

  2017cites this paper
• In vivo monitoring of the anti-angiogenic therapeutic effect of the pan-deacetylase inhibitor panobinostat by small animal PET in a mouse model of gastrointestinal cancers.

  2016cites this paper
• An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin’s lymphoma

  2016cites this paper
• HDAC inhibition activates the apoptosome via Apaf1 upregulation in hepatocellular carcinoma

  2016cites this paper
• Epigenetic Changes and Potential Targets in Pancreatic Cancer

  2016cites this paper
• Discovery of PAT-1102, a novel, potent and orally active histone deacetylase inhibitor with antitumor activity in cancer mouse models.

  2015cites this paper
• More is better: combination therapies for myelodysplastic syndromes.

  2015cites this paper
• Emerging drugs for the treatment of cervical cancer

  2015cites this paper
• Angiogeneza i limfangiogeneza w pierwotnie skórnych chłoniakach T-komórkowych* Angiogenesis and lymphangiogenesis in primary cutaneous T-cell lymphomas

  2015cites this paper
• The pan-deacetylase inhibitor panobinostat affects angiogenesis in hepatocellular carcinoma models via modulation of CTGF expression.

  2015cites this paper
• [Angiogenesis and lymphangiogenesis in primary cutaneous T-cell lymphomas].

  2015cites this paper
• Role of histone deacetylases in pancreas: Implications for pathogenesis and therapy.

  2015cites this paper
• Preclinical antitumor activity of ST7612AA1: a new oral thiol-based histone deacetylase (HDAC) inhibitor

  2014cites this paper
• Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects.

  2014cites this paper
• The pan-deacetylase inhibitor panobinostat modulates the expression of epithelial-mesenchymal transition markers in hepatocellular carcinoma models.

  2013cites this paper
• Biologics: Targets and Therapy

  2013influential citation
• Cellular responses with thymoquinone treatment in human breast cancer cell line MCF-7

  2013cites this paper
• [Histone deacetylase inhibitors - molecular mechanisms of actions and clinical applications].

  2013cites this paper
• Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells.

  2012cites this paper
• Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines

  2012cites this paper
• Combination of the Deacetylase Inhibitor Panobinostat and the Multi-Kinase Inhibitor Sorafenib for the Treatment of Metastatic Hepatocellular Carcinoma - Review of the Underlying Molecular Mechanisms and First Case Report

  2012cites this paper
• DNMT (DNA methyltransferase) inhibitors radiosensitize human cancer cells by suppressing DNA repair activity

  2012cites this paper
• Emerging drugs for cervical cancer

  2012cites this paper
• New drugs, old fashioned ways: ER stress induced cell death.

  2012cites this paper
• Applications of Connectivity Map in drug discovery and development.

  2012cites this paper
• Quantitative proteomic analysis of chromatin-bound proteins in the fission yeast Schizosaccharomyces pombe

  2012cites this paper
• Compendia of Public Gene Expression Data Discovery and Preclinical Validation of Drug Indications Using

  2011cites this paper
• DNMT3a plays a role in switches between doxorubicin‐induced senescence and apoptosis of colorectal cancer cells

  2011cites this paper
• DNA Methyltransferase Controls Stem Cell Aging by Regulating BMI1 and EZH2 through MicroRNAs

  2011cites this paper
• Myelodysplastic Syndrome and Histone Deacetylase Inhibitors: “To Be or Not to Be Acetylated”?

  2011influential citation
• Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data

  2011cites this paper
• Preclinical studies on histone deacetylase inhibitors as therapeutic reagents for endometrial and ovarian cancers.

  2011cites this paper
• Gene Regulation by Drugs Used to Treat Mood Disorders

  2011cites this paper
• Down-regulation of VEZT gene expression in human gastric cancer involves promoter methylation and miR-43c.

  2011cites this paper
• The Pan-Deacetylase Inhibitor Panobinostat Inhibits Growth of Hepatocellular Carcinoma Models by Alternative Pathways of Apoptosis

  2010cites this paper
• Array-based profiling of the differential methylation status of CpG islands in hepatocellular carcinoma cell lines.

  2010cites this paper
• Homeobox gene IRX1 is a tumor suppressor gene in gastric carcinoma

  2010cites this paper
• Nonhistone protein acetylation as cancer therapy targets

  2010cites this paper
• Aberrations of the Epigenome in Gliomas: Novel Targets for Therapy

  2010cites this paper
• Deacetylase inhibitors - focus on non-histone targets and effects.

  2010cites this paper
• Roadblocks en route to the clinical application of induced pluripotent stem cells

  2010cites this paper
• Altered DNA methylation is associated with docetaxel resistance in human breast cancer cells.

  2010cites this paper
• Anticancer Activity and Differentially Expressed Genes in Head and Neck Cancer Cells Treated with a Novel Cyclin-Dependent Kinase Inhibitor

  2009cites this paper
• HtrA serine proteases as potential therapeutic targets in cancer.

  2009cites this paper
• Loss of NECL1, a novel tumor suppressor, can be restored in glioma by HDAC inhibitor‐Trichostatin A through Sp1 binding site

  2009cites this paper
• DNA methylation of cancer genome.

  2009cites this paper
• Differential regulation of connective tissue growth factor in renal cells by histone deacetylase inhibitors

  2009cites this paper
• Potential of DNMT and its Epigenetic Regulation for Lung Cancer Therapy

  2009cites this paper
• Overview of Major Classes of Plant-Derived Anticancer Drugs

  2009cites this paper
• Connective tissue growth factor: Context‐dependent functions and mechanisms of regulation

  2009cites this paper
• Novel amide derivatives as inhibitors of histone deacetylase: design, synthesis and SAR.

  2009cites this paper
• Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review).

  2008cites this paper
• The histone-deacetylase inhibitor MS-275 and the CDK-inhibitor CYC-202 promote anti-tumor effects in hepatoma cell lines.

  2008cites this paper
• Alkylation damage causes MMR-dependent chromosomal instability in vertebrate embryos

  2008cites this paper
• Valproate protective effects on cisplatin-induced peripheral neuropathy: an in vitro and in vivo study.

  2008cites this paper
• HDAC inhibitors: a potential new category of anti-tumor agents.

  2007cites this paper